Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats

Psychopharmacology

Volumn 187, Issue 2, 2006, Pages 237-244

  Salome N ^a   Stemmelin, J ^a   Cohen, C ^a   Griebel, G ^a  

^a SANOFI   (France)

Author keywords

Amygdaloid nuclei; Anxiety; Depression; Elevated plus maze; Forced swimming test; Rat; SSR149415; V1b receptor; Vasopressin

Indexed keywords

1 [5 CHLORO 1 (2,4 DIMETHOXYLPHENYLSULFONYL) 2,3 DIHYDRO 3 (2 METHOXYPHENYL) 2 OXO 1H INDOL 3 YL] 4 HYDROXY N,N DIMETHYL 2 PYRROLIDINECARBOXAMIDE; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V1B RECEPTOR;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INFUSION; DRUG SCREENING; DRUG USE; EMOTION; FORCED SWIMMING TEST; IMMOBILIZATION; MALE; MAZE TEST; MICROINJECTION; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; RAT STRAIN; TISSUE STRUCTURE; TRANQUILIZING ACTIVITY;

AFFECT; AMYGDALA; ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; AROUSAL; BRAIN MAPPING; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCAPE REACTION; FEAR; INDOLES; MALE; MAZE LEARNING; MICROINJECTIONS; MOTIVATION; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VASOPRESSIN; SWIMMING;

EID: 33745746050     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-006-0424-1     Document Type: Article

References (51)

1. Aguilera G, Rabadan-Diehl C (2000) Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation. Regul Pept 96:23-29
2. Andrea LC, Herbert J (1993) Expression of c-fos in restricted areas of intraventricular infusions of vasopressin and corticotropin-releasing factor. Neuroscience 53:735-748
3. Araki H, Kawashima K, Aihara H (1984) The difference in the site of actions of tricyclic antidepressants and methamphetamine on the duration of the immobility in the behavioral despair test. Jpn J Pharmacol 35:67-72
4. Caffé AR, van Leeuwen FW (1983) Vasopressin-immunoreactive cells in the dorsomedial hypothalamic region, medial amygdaloid nucleus and locus coeruleus of the rat. Cell Tissue Res 233:23-33
5. Caffé AR, van Leeuwen FW, Luiten PG (1987) Vasopressin cells in the medial amygdala of the rat project to the lateral septum and ventral hippocampus. J Comp Neurol 261:237-252
6. Chen X, Herbert J (1995) Alterations in sensitivity to intracerebral vasopressin and the effects of a V1a receptor antagonist on cellular, autonomic and endocrine responses to repeated stress. Neuroscience 64:687-697
7. Davis M, Whalen PJ (2001) The amygdala: vigilance and emotion. Mol Psychiatry 6:13-34
8. De Vries GJ, Buijs RM (1983) The origin of the vasopressinergic and oxytocinergic innervation of the rat brain with special reference to the lateral septum. Brain Res 273:307-317
9. Dorsa DM, Petracca FM, Baskin DG, Cornett LE (1984) Localization and characterization of vasopressin-binding sites in the amygdala of the rat brain. J Neurosci 4:1764-1770
10. Drevets W (2001) Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 11:240-249
11. Duncan GE, Breese GR, Criswell H, Stumpf WE, Mueller RA, Covey JB (1986) Effects of antidepressant drugs injected into the amygdala on behavioral responses of rats in the forced swim test. J Pharmacol Exp Ther 238:758-762
12. Duncan GE, Johnson KB, Breese GR (1993) Topographic patterns of brain activity in response to swim stress: assessment by 2-deoxyglucose uptake and expression of Fos-like immunoreactivity. J Neurosci 13:3932-3943
13. Duxon MS, Beckett SRG, Baxter GS, Blackburn TP, Fone (1995) Intra-amygdala injection of the 5-HT2B receptor agonist BW 723C86 produces anxiolysis on the elevated plus-maze in the rat. Br J Pharmacol 115:105P
14. Duxon MS, Kennett GA, Lightowler S, Blackburn TP (1997) Activation of 5-HT2B receptors in the medial amygdala causes anxiolysis in the social interaction test in the rat. Neuropharmacology 36:601-608
15. Ebner K, Wotjak CT, Holsboer F, Landgraf R, Engelmann M (1999) Vasopressin released within the septal brain area during swim stress modulates the behavioural stress response in rats. Eur J Neurosci 11:997-1002
16. Ebner K, Wotjak CT, Landgraf R, Engelmann M (2002) Forced swimming triggers vasopressin release within the amygdala to modulate stress-coping strategies in rats. Eur J Neurosci 15:384-388
17. Ebner K, Rupniak NM, Saria A, Singewald N (2004) Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc Natl Acad Sci USA 23:4280-4285
18. Gonzalez LE, Andrews N, File SE (1996) 5-HT1A and benzodiazepine receptors in the basolateral amygdala modulate anxiety in the social interaction test, but not in the elevated plus-maze. Brain Res 732:145-153
19. Gorka Z, Ossowska K, Stach R (1979) The effect of unilateral amygdala lesion on the imipramine action in the behavioral despair in rats. J Pharm Pharmacol 31:647-648
20. Green S, Vale AL (1992) Role of amygdaloid nuclei in the anxiolytic effects of benzodiazepines in rats. Behav Pharmacol 3:261-264
21. Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B et al (2002) Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA 99:6370-6375
22. Griebel G, Simiand J, Stemmelin J, Serradeil-Le Gal C, Steinberg R (2003) The vasopressin V1b receptor as a therapeutic target in stress-related disorders. Curr Drug Target CNS Neurol Disord 2:191-200
23. Hasting RS, Parsey RV, Oquendo MA, Arango V, Mann JJ (2004) Volumetric analysis of the prefrontal cortex, amygdala, and hippocampus in major depression. Neuropsychopharmacology 29:952-959
24. Hernando F, Schools O, Lolait SJ, Burbach JP (2001) Immunohistochemical localization of the vasopressin V1b receptor in the rat brain and pituitary gland: anatomical support for its involvement in the central effects of vasopressin. Endocrinology 142:1659-1668
25. Ho Y, Liu T, Tai M, Wen Z, Chow RS, Tsai Y, Wong C (2001) Effects of olfactory bulbectomy on NMDA receptor density in the rat brain. Brain Res 900:214-218
26. Huber D, Veinante P, Stoop R (2005) Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. Science 308:245-248
27. Kataoka Y, Shibata Z, Yamashita K, Ueki S (1987) Differential mechanisms involved in the anticonflict action of benzodiazepines injected into the central amygdala and mamillary body. Brain Res 416:243-247
28. Killcross S, Robbins TW, Everitt BJ (1997) Different types of fear-conditioned behaviour mediated by separate nuclei within amygdala. Nature 388:377-380
29. Landgraf R, Gerstberger R, Montkowski A, Probst JC, Wotjak CT, Holsboer F et al (1995) V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats. J Neurosci 15:4250-4258
30. Massana G, Serra-Grabulosa JM, Salgado-Pineda P, Gasto C, Junque C, Massana J, Mercader JM, Gomez B, Tobena A, Salamero M (2003) Amygdalar atrophy in panic disorder patients detected by volumetric magnetic resonance imaging. Neuroimage 19:80-90
31. Menard J, Treit D (1999) Effects of centrally administered anxiolytic compounds in animal models of anxiety. Neurosci Biobehav Rev 23:591-613
32. Paxinos G, Watson W (1998) The rat brain in stereotaxic coordinates, 4th edn. Academic, London
33. Pellow S, Chopin P, File SE, Briley M (1985) Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149-167
34. Pesold C, Treit D (1995) The central and basolateral amygdala differentially mediate the anxiolytic effects of benzodiazepines. Brain Res 671:213-221
35. Porsolt R, Le Pichon M, Jalfre M (1977) Depression: a new animal model sensitive to antidepressant treatments. Nature 266:730-732
36. Rabadan-Diehl C, Makara G, Kiss A, Lolait S, Zelena D, Ochedalski T et al (1997) Regulation of pituitary V1b vasopressin receptor messenger ribonucleic acid by adrenalectomy and glucocorticoid administration. Endocrinology 138:5189-5194
37. Rutkoski NJ, Lerant AA, Nolte CM, Westberry J, Levenson CW (2002) Regulation of neuropeptide Y in the rat amygdala following unilateral olfactory bulbectomy. Brain Res 951:69-76
38. Salchner P, Singewald N (2002) Neuroanatomical substrates involved in the anxiogenic-like effect of acute fluoxetine treatment. Neuropharmacology 43:1238-1248
39. Serradeil-Le Gal C, Wagnon J, Simiand J, Griebel G, Lacour C, Guillon G et al (2002) Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl) sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N, N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J Pharmacol Exp Ther 300:1122-1130
40. Sheline Y, Gado MH, Price JL (1998) Amygdala core nuclei volumes are decreased in recurrent major depression. J Neurosci 22:3251-3261
41. Shibata S, Watanabe S (1994) Facilitatory effect of olfactory bulbectomy on 2-deoxyglucose uptake in rat amygdala slices. Brain Res 665:147-150
42. Shibata K, Kataoka Y, Gomita Y, Ueki S (1982) Localization of the site of the anticonflict action of benzodiazepines in the amygdaloid nucleus of rats. Brain Res 234:442-446
43. Sofroniew MV (1985) Vasopressin- and neurophysin-immunoreactive neurons in the septal region, medial amygdala and locus coeruleus in colchicine-treated rats. Neuroscience 15:347-358
44. Stemmelin J, Lukovic L, Salome N, Griebel G (2005) Evidence that the lateral septum is involved in the antidepressant-like effects of the vasopressin V1b receptor antagonist, SSR149415. Neuropsychopharmacology 30:35-42
45. Tanoue A, Ito S, Honda K, Oshikawa S, Kitagawa Y, Koshimizu TA, Mori T, Tsujimoto G (2004) The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. J Clin Invest 113:302-309
46. Veinante P, Freund-Mercier (1997) Distribution of oxytocin- and vasopressin-binding sites in the rat extended amygdala: a histoautoradiographic study. J Comp Neurol 38:305-325
47. Wilensky AE, Schafe GE, LeDoux JE (2000) The amygdala modulates memory consolidation of fear-motivated inhibitory avoidance learning but not classical fear conditioning. J Neurosci 20:7059-7066
48. Wu PH, Lança AJ, Liu JF, Man CF, Kalant H (1995) Peripheral injection of arginine8-vasopressin increases Fos in specific brain areas. Eur J Pharmacol 281:263-269
49. Wrynn AS, Sebens JB, Koch T, Leonard BE, Korf J (2000) Prolonged c-Jun expression in the basolateral amygdala following bulbectomy: possible implications for antidepressant activity and time of onset. Brain Res Mol Brain Res 76:7-17
50. Zangrossi H, Graeff FG (1994) Behavioral effects of intra-amygdala injections of GABA and 5-HT acting drug in the elevated plus maze. Braz J Med Biol Res 27:2453-2456
51. Zangrossi Jr H, Viana MB, Graeff FG (1999) Anxiolytic effect of intra-amygdala injection of midazolam and 8-hydroxy-2-(di-n-propylamino)tetralin in the elevated T-maze. Eur J Pharmacol 369:267-270